iShares Diversified Alternatives Trust (NYSEARCA:ALT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company’s proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States. “
NYSEARCA:ALT opened at $3.71 on Thursday. iShares Diversified Alternatives Trust has a fifty-two week low of $3.55 and a fifty-two week high of $70.80.
iShares Diversified Alternatives Trust (the Trust) is a commodity pool. The investment objective of the Trust is to maximize absolute returns from its investments in certain futures and/or forward contracts. The Trust holds long and/or short positions in foreign currency forward contracts and exchange-traded futures contracts involving assets, such as commodities, currencies, interest rates or certain eligible stock and/or bond indices.
Further Reading: Technical Analysis of Stocks, How Can It Help
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for iShares Diversified Alternatives Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Diversified Alternatives Trust and related companies with MarketBeat.com's FREE daily email newsletter.